Pacira BioSciences, Inc. (PCRX)
Pacira BioSciences sells pain treatments such as EXPAREL and ZILRETTA to patients and healthcare providers. It last closed at $36.48 on Nov 16, up 0.05% on the day. The average 12-month price target from 7 analysts is $34.57 (-5.2% from the last close), with a high of $36.50 and a low of $28.00. Analyst consensus is Hold, based on the latest ratings from 7 firms (1 buy, 6 hold, 0 sell). In the past 30 days there were 2 dark pool prints totaling $7.1M, the largest $6.1M.
Key Stats
Last 12 monthsNot reported for this period.
From PCRX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 7 analysts who set a price target on PCRX in the past 90 days. The average target is $34.57, with a high of $36.50 and a low of $28.00, compared with the last close of $36.48.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 9 | Truist Securities | Downgrade | Hold | $36.50 |
| Oct 9 | RBC Capital | Target raised | Hold | $25 → $36.50 |
| Oct 9 | HC Wainwright & Co. | Downgrade | Hold | $36.50 |
| Oct 8 | JP Morgan | Upgrade | Hold | $36.50 |
| Oct 8 | Jefferies | Downgrade | Hold | $36 |
Technical Analysis
The stock is 0% above its 20 day and 14% above its 50 day average. It is 29% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 83), overbought. The nearest support is the 20 day average at $36.41, and the nearest resistance the Pivot R1 at $36.49.
| RSI (14) | 82.85 | Overbought above 70 | Overbought |
| MACD | 1.23 | Below its signal line | Bearish |
| Stochastic | 64.8 | Middle of its range | Neutral |
| ADX (14) | 69.4 | Strong uptrend | |
| Williams %R | -27.8 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 127.2 | Oversold below −100, overbought above 100 | Overbought |
| Rate of change | +0.2% | Change over 10 sessions | Bullish |
| ATR (14) | $0.26 | Typical daily range, 0.7% of price |
| RSI (14) | 77.66 | Overbought above 70 | Overbought |
| MACD | 3.38 | Above its signal line | Bullish |
| Stochastic | 98.5 | Near the top of its range | Overbought |
| ADX (14) | 30.5 | Trending up | |
| Williams %R | -1.4 | Oversold below −80, overbought above −20 | Overbought |
| CCI (20) | 103.9 | Oversold below −100, overbought above 100 | Overbought |
| Rate of change | +43.9% | Change over 10 sessions | Bullish |
| ATR (14) | $1.72 | Typical daily range, 4.7% of price |
What happened before
See how PCRX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How PCRX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2011.
Whale Options Flow
90DNo whale options trades in PCRX in the last 90 days.
Dark Pool
30DPCRX Institutional Ownership
Full report →- ●125 buying vs 111 selling
- ▲Held by funds +10.5 pts
- ▲Funds holding +5
- ▼Superinvestors: 0 added, 3 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 261 | 256 | +2.0% |
| In funds' top 10 | 3 | 2 | +50.0% |
| Held by funds | 143.3% | 132.8% | +10.5 pts |
| New / increased | 30 / 95 | 36 / 82 | +5.9% |
| Reduced / sold out | 86 / 25 | 84 / 26 | +0.9% |
| Put/call ratio | – | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PCRX is in one of them and how their past PCRX trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered PCRX in an article yet. Here's the latest on the wider market.
PCRX Congress Trades
All congress trades →| Person | Type | Amount | Traded | Filed | Delay |
|---|---|---|---|---|---|
| Donald J TrumpExecutive branch | Buy | $15K – $50K | Jan 30, 2026 | May 14, 2026 | 104 d |
| Tom MalinowskiD · NJ | Buy | $1K – $15K | May 6, 2021 | Jun 23, 2021 | 48 d |
| Tom MalinowskiD · NJ | Buy | $1K – $15K | Apr 20, 2021 | Jun 12, 2021 | 53 d |
| Tom MalinowskiD · NJ | Buy | $1K – $15K | Jan 15, 2021 | Mar 5, 2021 | 49 d |
| Tom MalinowskiD · NJ | Buy | $1K – $15K | Nov 2, 2020 | Mar 5, 2021 | 123 d |
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Pacira BioSciences
Pacira BioSciences is a pharmaceutical company based in Brisbane, California. It sells pain treatments that do not rely on opioids. Its main products are EXPAREL, a local pain treatment used around surgery that works over an extended period, ZILRETTA, a knee injection that releases medicine over time for osteoarthritis pain, and the iovera handheld device, which uses cold to block pain signals in targeted nerves. Its customers include patients and the healthcare providers who treat them.
- Headquarters
- Brisbane, CA




